New biologic TRK-950 joins forces with standard chemo to fight stomach cancer

NCT ID NCT06038578

Recruiting now Disease control Sponsor: Toray Industries, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding an experimental biologic called TRK-950 to the standard combination of ramucirumab and paclitaxel helps people with advanced stomach or gastroesophageal junction cancer. Participants receive either the standard two-drug regimen or the standard regimen plus TRK-950 at one of two dose levels. The study measures how long the cancer stays under control, overall survival, and tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TRK-950 (a biologic) plus ramucirumab and paclitaxel
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced gastric cancer that has worsened after prior therapy.
What could go wrong: This is an early-phase trial with a small number of participants. The experimental drug may not improve outcomes and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA GASTRIC CANCER GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

ASAN Medical Center
RECRUITING

Seoul, 05505, South Korea
Chonnam National University Hwasun Hospital
RECRUITING

Hwasun, Jeollanam-do, 58128, South Korea
City of Hope
RECRUITING

Duarte, California, 91010, United States
City of Hope at Orange County Lennar Foundation Cancer Center
RECRUITING

Irvine, California, 92618, United States
Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
RECRUITING

Yokohama, Kanagawa, 241-8515, Japan
Kyungpook National University Chilgok Hospital
RECRUITING

Daegu, 41404, South Korea
National Cancer Center Hospital
RECRUITING

Chūōku, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa, 277-8577, Japan
Osaka International Cancer Institute
RECRUITING

Chūōku, 541-8567, Japan
Saitama Prefectural Hospital Organization Saitama Cancer Center
RECRUITING

Shinden, Saitama, 362-0806, Japan
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul National University Bundang Hospital
RECRUITING

Seongnam-si, Gyeonggi-do, 13605, South Korea
Severance Hospital
RECRUITING

Seoul, 03722, South Korea
Shizuoka Cancer Center
RECRUITING

Nagaizumi-cho, Shizuoka, 411-8777, Japan
Texas Oncology Arlington North
RECRUITING

Arlington, Texas, 76012, United States
Texas Oncology Bedford
RECRUITING

Bedford, Texas, 76022, United States
Texas Oncology Dallas Medical City
RECRUITING

Dallas, Texas, 75230, United States
Texas Oncology Dallas Methodist
RECRUITING

Dallas, Texas, 75203, United States
Texas Oncology Dallas Presbyterian
RECRUITING

Dallas, Texas, 75231, United States
Texas Oncology Fort Worth Cancer Center
RECRUITING

Fort Worth, Texas, 76104, United States
Texas Oncology Grapevine
RECRUITING

Grapevine, Texas, 76051, United States
Texas Oncology Methodist Charlton Cancer Center
RECRUITING

Dallas, Texas, 75237, United States
Texas Oncology Plano East
RECRUITING

Plano, Texas, 75075, United States
Texas Oncology Plano West
RECRUITING

Plano, Texas, 75093, United States
Texas Oncology-Sammons Cancer Center
RECRUITING

Dallas, Texas, 75246, United States
The Cancer Institute Hospital of JFCR
RECRUITING

Kōtoku, 135-8550, Japan
University of California, Los Angeles
RECRUITING

Santa Monica, California, 90404, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.